HIV immunotherapeutic consisting of inactivated data

IMNR (Carlsbad, Calif.) published results of a dose-ranging Phase II trial in 48 infected, asymptomatic AIDS patients, showing that 100 µg is the minimum dose needed to elicit a delayed hypersensitivity response (DTH), compared to controls who received only the adjuvant.

Skin testing of the DTH response is indicative of cell-mediated immune responses, although the investigators noted that the clinical implications of the response they obtained remain to be determined. ...